Zev A Wainberg Selected Research

2- amino- 8- (4- (2- hydroxyethoxy)cyclohexyl)- 6- (6- methoxypyridin- 3- yl)- 4- methylpyrido(2,3- d)pyrimidin- 7(8H)- one

12/2017	A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer.
6/2014	Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Zev A Wainberg Research Topics

Disease

50	Neoplasms (Cancer) 01/2022 - 02/2007
26	Adenocarcinoma 02/2022 - 01/2013
15	Colorectal Neoplasms (Colorectal Cancer) 01/2021 - 07/2007
13	Stomach Neoplasms (Stomach Cancer) 01/2022 - 03/2010
8	Pancreatic Neoplasms (Pancreatic Cancer) 01/2022 - 12/2015
7	Disease Progression 01/2021 - 12/2015
4	Neutropenia 12/2021 - 01/2019
4	Diarrhea 12/2021 - 12/2013
3	Exanthema (Rash) 01/2021 - 02/2015
3	Neoplasm Metastasis (Metastasis) 01/2021 - 12/2010
3	Vomiting 01/2020 - 02/2017
3	Urinary Bladder Neoplasms (Bladder Cancer) 01/2020 - 03/2010
3	Colonic Neoplasms (Colon Cancer) 01/2019 - 09/2009
2	Giant Cell Tumor of Tendon Sheath 01/2021 - 07/2015
2	Giant Cell Tumors (Giant Cell Tumor) 01/2021 - 07/2015
2	Septic Shock (Toxic Shock Syndrome) 01/2021 - 01/2019
2	Biliary Tract Neoplasms (Biliary Tract Cancer) 11/2020 - 01/2020
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2020 - 01/2017
2	Anemia 01/2020 - 12/2015
2	Nausea 01/2020 - 02/2017
2	Hypertension (High Blood Pressure) 01/2019 - 01/2013
2	Ovarian Neoplasms (Ovarian Cancer) 12/2017 - 02/2015
2	Breast Neoplasms (Breast Cancer) 06/2017 - 04/2013
2	Fatigue 02/2017 - 12/2013
1	Edema (Dropsy) 04/2022
1	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 01/2022
1	Microsatellite Instability 06/2021
1	Sepsis (Septicemia) 01/2021
1	Carcinoma (Carcinomatosis) 11/2020
1	Hepatocellular Carcinoma (Hepatoma) 01/2020

Drug/Important Bio-Agent (IBA)

11	Monoclonal AntibodiesIBA 01/2021 - 12/2010
9	Biomarkers (Surrogate Marker)IBA 02/2022 - 09/2009
9	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2021 - 12/2013
8	pembrolizumabIBA 01/2022 - 10/2018
8	Bevacizumab (Avastin)FDA Link 10/2017 - 01/2012
7	Gemcitabine FDA Link 01/2021 - 12/2015
6	Irinotecan (Camptosar)FDA LinkGeneric 12/2021 - 12/2013
5	Leucovorin (Folinic Acid)FDA Link 01/2021 - 12/2013
5	ErbB Receptors (EGF Receptor)IBA 01/2021 - 07/2007
5	Capecitabine (Xeloda)FDA Link 06/2017 - 10/2013
4	NivolumabIBA 01/2022 - 01/2020
4	RamucirumabIBA 01/2021 - 01/2019
4	Fluorouracil (Carac)FDA LinkGeneric 01/2021 - 12/2013
4	Cetuximab (Erbitux)FDA Link 01/2021 - 01/2015
4	trametinibIBA 11/2020 - 02/2015
4	Immunoglobulin G (IgG)IBA 01/2020 - 01/2017
3	talazoparibIBA 01/2022 - 01/2017
3	pexidartinibIBA 01/2022 - 07/2015
3	Paclitaxel (Taxol)FDA LinkGeneric 11/2021 - 01/2019
3	Panitumumab (Vectibix)FDA Link 01/2021 - 07/2007
3	EnzymesIBA 01/2021 - 08/2014
3	andecaliximabIBA 01/2021 - 01/2018
3	130-nm albumin-bound paclitaxelIBA 01/2021 - 01/2020
3	dabrafenibIBA 11/2020 - 01/2018
3	durvalumabIBA 01/2020 - 10/2016
3	Pharmaceutical PreparationsIBA 01/2019 - 04/2013
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2019 - 01/2012
3	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2018 - 08/2014
3	Lapatinib (GW572016)FDA Link 06/2017 - 03/2010
3	Phosphotransferases (Kinase)IBA 01/2017 - 03/2010
2	Tyrosine Kinase InhibitorsIBA 01/2022 - 01/2017
2	Macrophage Colony-Stimulating FactorIBA 01/2022 - 07/2015
2	sotigalimabIBA 01/2022 - 01/2021
2	PlatinumIBA 10/2021 - 01/2019
2	GSK 1363089IBA 01/2021 - 01/2013
2	avelumabIBA 01/2021 - 02/2019
2	Matrix Metalloproteinase 9 (Gelatinase B)IBA 01/2021 - 11/2020
2	B7-H1 AntigenIBA 01/2021 - 10/2018
2	Circulating Tumor DNAIBA 01/2020 - 01/2019
2	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2019 - 12/2013
2	2- amino- 8- (4- (2- hydroxyethoxy)cyclohexyl)- 6- (6- methoxypyridin- 3- yl)- 4- methylpyrido(2,3- d)pyrimidin- 7(8H)- oneIBA 12/2017 - 06/2014
2	parsatuzumabIBA 10/2017 - 01/2017
2	Epidermal Growth Factor (EGF)IBA 01/2017 - 07/2007
2	Aspartate Aminotransferases (Aspartate Transaminase)IBA 02/2015 - 01/2013
2	Adrenal Cortex Hormones (Corticosteroids)IBA 08/2014 - 02/2007
2	Trastuzumab (Herceptin)FDA Link 04/2013 - 03/2010
2	Proteins (Proteins, Gene)FDA Link 01/2013 - 03/2010
2	Cadherins (E-Cadherin)IBA 12/2010 - 03/2010
1	tyramine-deoxysorbitolIBA 04/2022
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 02/2022
1	IpilimumabIBA 01/2022
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2022
1	fms-Like Tyrosine Kinase 3IBA 01/2022
1	Silicon Dioxide (Silica)FDA LinkGeneric 03/2021
1	CalreticulinIBA 03/2021
1	Lipid Bilayers (Lipid Bilayer)IBA 03/2021
1	HMGB1 Protein (HMG1)IBA 03/2021
1	LUT014IBA 01/2021
1	pegilodecakinIBA 01/2021
1	LigandsIBA 10/2020
1	tremelimumabIBA 01/2020

Therapy/Procedure

30	Therapeutics 02/2022 - 07/2007
20	Drug Therapy (Chemotherapy) 02/2022 - 02/2007
4	Immunotherapy 01/2022 - 01/2021
2	Adjuvant Chemotherapy 02/2015 - 09/2009
1	Pancreatectomy 01/2022
1	Duration of Therapy 01/2022
1	Chemoradiotherapy 01/2022
1	Neoadjuvant Therapy 01/2022
1	Induction Chemotherapy 01/2021